News >

FDA Lifts Partial Clinical Hold on Tazemetostat Trials

Jason Harris
Published: Monday, Sep 24, 2018

Robert Bazemore
Robert Bazemore
The FDA has lifted a partial clinical hold on tazemetostat trials, reopening enrollment to clinical studies examining the EZH2 inhibitor in patients with various solid tumors and hematologic malignancies.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication